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Abstract	
The	 genes	 encoding	 the	 histone	 acetyl-transferases	 (HATs)	 CREBBP	 and	 EP300	 are	 recurrently	
mutated	 in	the	activated	B-cell-like	and	germinal	center	 (GC)	B-cell-like	subtypes	of	diffuse	 large	B-
cell	 lymphoma	(DLBCL).	Here	we	 introduced	a	patient	mutation	 into	a	human	DLBCL	cell	 line	using	
CRISPR	and	deleted	Crebbp	and	Ep300	in	the	GC	B-cell	compartment	of	mice.	CREBBP-mutant	DLBCL	
clones	exhibited	reduced	histone	H3	acetylation,	expressed	significantly	 less	MHCII	and	grew	faster	
than	wild	type	clones	in	subcutaneous	and	orthotopic	xenograft	models.	Mice	lacking	Crebbp	in	GC	
B-cells	exhibited	hyperproliferation	of	their	GC	compartment	upon	immunization,	had	reduced	MHCII	
surface	 expression	 on	 GC	 cells,	 and	 developed	 accelerated	 MYC-driven	 lymphomas.	 Ep300	
inactivation	 reproduced	 some,	 but	 not	 all,	 consequences	 of	 Crebbp	 inactivation.	MHCII	 deficiency	
phenocopied	 the	effects	of	CREBBP	 loss	 in	 spontaneous	and	serial	 transplantation	models	of	MYC-
driven	lymphomagenesis,	supporting	the	idea	that	the	mutational	 inactivation	of	CREBBP	promotes	
immune	 evasion.	 Indeed,	 the	 depletion	 of	 CD4+	 T-cells	 greatly	 facilitated	 the	 engraftment	 of	
lymphoma	cells	 in	 serial	 transplantation	models.	 In	 summary,	we	provide	evidence	 that	both	HATs	
are	bona	fide	tumor	suppressors	that	control	MHCII	expression	and	promote	tumor	immune	control;	
mutational	 inactivation	 of	 CREBBP,	 but	 not	 of	 EP300,	 has	 additional	 cell-intrinsic	 engraftment	 and	
growth-promoting	effects.		
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Significance	statement	
Genes	 encoding	 chromatin-modifying	 enzymes	 such	 as	 the	 histone	 acetyl-transferases	 (HATs)	 are	
often	 mutated	 in	 diffuse	 large	 B-cell	 lymphoma	 (DLBCL),	 the	 most	 common	 lymphoma	 of	 adults.	
Here,	we	shed	light	on	the	tumor	suppressive	activity	of	HATs	in	human	DLBCL	cell	lines	and	in	mice.	
Cell	 lines	 harboring	 an	 experimentally	 introduced	 patient	 mutation	 in	 the	 HAT	 CREBBP	 lose	 their	
MHCII	 expression	 and	 form	 tumors	 faster	 in	 subcutaneous	 and	orthotopic	 xenograft	models.	Mice	
that	 lack	 Crebbp	 specifically	 in	 the	 germinal	 center	 B-cell	 compartment	 also	 lose	 their	 MHCII	
expression	 in	 that	 compartment,	 and	 show	 hyper-proliferation	 of	 germinal	 center	 B-cells	 upon	
immunization,	which	predisposes	them	to	MYC-driven	lymphomagenesis.	Our	data	implicate	HATs	as	
novel	tumor	suppressors	in	DLBCL.	
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Introduction	
Perturbations	 of	 the	 epigenome	 due	 to	 mutations	 occurring	 in	 histone-modifying	 enzymes	 are	
emerging	as	a	driving	force	in	the	pathogenesis	of	diffuse	large	B-cell	lymphoma	(DLBCL)	(1).	The	two	
main	 cell-of-origin	 subtypes	 of	 DLBCL,	 the	 activated	 B-cell-	 (ABC)	 and	 germinal	 center	 B-cell-like	
(GCB)	 subtype,	 are	 both	 commonly	 affected	 by	 mutations	 in	 epigenetic	 modifiers	 (2).	 The	 most	
common	recurrent	somatic	mutations	 in	histone-modifying	enzymes	are	 loss-of-function	mutations	
of	the	histone	methyltransferase	(HMT)	KMT2D	(also	known	as	MLL2),	gain-of-function	mutations	of	
the	HMT	EZH2,	and	loss-of-function	mutations	of	the	histone	acetyltransferases	CREBBP	and	EP300.	
Together,	 these	 somatic	 mutations	 occur	 in	 approximately	 50%	 of	 DLBCL	 patients	 (2),	 and	 are	
believed	to	be	founder	events	that	predispose	normal	B-cells	to	malignant	transformation	(1).	DLBCL	
is	 characterized	by	extraordinary	genetic	diversity,	both	within	and	across	 tumors,	which	has	been	
linked	largely	to	the	activity	of	activation-induced	cytidine	deaminase	(AID),	the	enzyme	responsible	
for	introducing	mutations	in	the	immunoglobulin	 locus	and	thereby	enabling	the	formation	of	high-
affinity	 antibodies,	 and	 its	 effects	 on	 non-immunoglobulin	 genes	 (3).	 More	 recently	 however,	
epigenetic	 heterogeneity	 has	 emerged	 as	 an	 equally	 important	 hallmark	 of	 DLBCL,	 with	 strong	
evidence	 for	 diversity	 in	 both	 DNA	 modifications	 (especially	 cytosine	 methylation)	 and	 the	 post-
translational	modifications	of	histones.	A	higher	degree	of	inter-	and	intratumoral	heterogeneity	has	
been	 associated	 directly	 with	 disease	 aggressiveness,	 likelihood	 of	 relapse	 and	 inferior	 patient	
survival	(4-6).	
The	contribution	of	mutations	 in	histone-modifying	enzymes	 to	DLBCL	 initiation	and	progression	 is	
subject	 to	 intense	 investigation.	 Loss-of-function	mutations	 in	KMT2D	 disrupt	histone	H3	 lysine	K4	
(H3K4)	 mono-	 and	 dimethylation	 and	 mostly	 affect	 gene	 enhancer	 regions,	 promoting	 the	
proliferation	of	GC	B-cells	and	preventing	their	terminal	differentiation	(7).	KMT2D	mutations	occur	
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in	23-32%	of	DLBCL	patients	(2,	8)	and	are	even	more	common	in	follicular	lymphoma	(FL);	in	animal	
models,	 KMT2D	 loss	 synergizes	 with	 BCL2	 to	 accelerate	 lymphomagenesis	 (7).	 Lymphomas	 from	
patients	with	gain-of-function	EZH2	mutations	show	aberrant	repression	of	GC-specific	proliferation	
checkpoint	genes	and	mice	engineered	to	express	mutant	EZH2	exhibit	a	massive	expansion	of	GC	B-
cells	due	to	aberrant	proliferation	and	differentiation	blockade	(9).	Mutations	in	CREBBP	and	EP300	
affect	over	30%	of	DLBCL	as	well	as	FL	patients,	and	usually	remove	or	inactivate	the	histone	acetyl-
transferase	 (HAT)	 coding	 domain	 of	 either	 gene	 (10);	 CREBBP	 in	 particular	 has	 been	 shown	 to	
function	 as	 part	 of	 an	 enhancer/super-enhancer	 network	 that	 regulates	 GC/post-GC	 cell	 fate	
decisions,	plasma	cell	differentiation	and	antigen	presentation	by	opposing	the	suppressive	activities	
of	BCL6/SMRT/HDAC3	complexes	(11,	12).		
Here	we	have	 investigated	 the	mutational	 status	of	CREBBP	 and	EP300	 in	a	panel	of	11	DLBCL	cell	
lines	relative	to	their	H3	acetylation.	CRISPR	technology	was	used	to	edit	the	CREBBP	locus	in	a	wild	
type	cell	line	and	CREBBP-mutant	and	wild	type	DLBCL	clones	were	subjected	to	xenotransplantation	
studies	in	subcutaneous	and	orthotopic	models.	We	further	generated	mice	with	a	Crebbp	deletion	
specifically	 in	 the	 germinal	 center	B-cell	 compartment	 and	 assessed	 the	 contribution	of	 Crebbp	or	
MHCII	 loss,	 and	 of	 CD4+	 T-cell	 depletion,	 to	 lymphomagenesis	 in	 spontaneous	 and	 serial	
transplantation	models	driven	by	the	overexpression	of	MYC.	All	available	evidence	from	the	various	
models	implicates	the	HATs	as	important	novel	tumor	suppressors	in	DLBCL	pathogenesis.	
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Results	
The	 CREBBP	 and	 EP300	 genomic	 loci	 are	 recurrently	 mutated	 in	 DLBCL	 cell	 lines,	 which	 affects	
histone	H3	acetylation	and	HLA	expression	
To	 determine	 the	mutational	 status	 of	 a	 panel	 of	 11	 DLBCL	 cell	 lines,	 we	 performed	 targeted	 re-
sequencing	of	the	31	exons	each	of	the	CREBBP	and	EP300	genomic	loci	(Fig.	1A).	Only	two	of	the	11	
cell	lines,	U-2932	and	OCI-Ly3,	were	found	to	be	wild	type	for	both	alleles	each	of	CREBBP	and	EP300,	
indicating	 that	 mutations	 targeting	 these	 loci	 were	 even	more	 common	 in	 our	 panel	 of	 cell	 lines	
(>80%;	Fig.	1A)	than	in	previously	examined	DLBCL	patient	cohorts	(2,	10).	The	two	CREBBP/EP300-
wild	type	cell	 lines	U-2932	and	OCI-Ly3	expressed	clearly	detectable	amounts	of	full	 length	CREBBP	
and	EP300	(Fig.	1B).	Of	the	remaining	nine	cell	lines,	three	exhibited	mono-	or	bi-allelic	mutations	or	
deletions	 of	 EP300,	 leading	 to	 the	 partial	 (SU-DHL-10)	 and	 complete	 (SU-DHL-2,	 RC-K8)	 loss,	
respectively,	 of	 EP300	 expression	 (Fig.	 1B).	 The	 acetylation	 of	 H3	 on	 residues	 K18	 and	 27,	 and	 to	
some	extent	on	K14,	was	reduced	in	the	three	EP300-mutant	cell	lines	relative	to	the	two	wild	type	
cell	 lines	 (Fig.	1B),	whereas	the	acetylation	 level	of	K9	did	not	mirror	 the	other	three	residues	 (Fig.	
S1A).	 The	 remaining	 six	 DLBCL	 cell	 lines	 exhibited	 evidence	 of	mono-allelic	 (5/6)	 or	 bi-allelic	 (1/6)	
mutational	inactivation	of	CREBBP	by	either	truncating	mutations	leading	to	immature	stop	codons,	
or	amino	acid	substitutions	or	chromosomal	translocations	that	detectably	affect	CREBBP	expression	
levels	 (Fig.	 1A,B).	 Reduced	 or	 prematurely	 truncated	 CREBBP	 expression	 coincided	 with	 strongly	
reduced	 H3K14,	 18	 and	 27	 acetylation	 in	 all	 CREBBP-mutant	 cell	 lines	 (Fig.	 1B),	 with	 the	 notable	
exception	 of	 SU-DHL-6,	 which	 maintains	 high	 level	 CREBBP	 expression	 due	 to	 a	 trisomy	 of	
chromosome	16.	 Interestingly,	mutations	 in	CREBBP	 and	EP300	were	mutually	exclusive	 in	our	cell	
line	panel	as	had	been	shown	previously	in	primary	DLBCL	samples	(2,	10),	and	the	loss	of	just	one	of	
the	 total	 of	 four	 CREBBP/EP300	 alleles	 was	 sufficient	 to	 produce	 a	 clear	 phenotype	 in	 terms	 of	
H3K14,	 18	 and	27	 acetylation	 (Fig.	 1A,B).	 In	 contrast,	 the	 acetylation	of	 P53,	which	has	 previously	
been	attributed	to	HATs	and	their	putative	activity	on	non-histone	targets	(10),	was	not	affected	by	
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single	copy	losses	of	CREBBP	or	EP300	(Fig.	S1B).	ABC-	and	GCB-DLBCL-derived	cell	lines	were	equally	
affected	by	CREBBP/EP300	mutational	inactivation.	
To	assess	in	a	more	controlled	setting	whether	CREBBP	and	EP300	expression	affects	H3	acetylation	
and	 histone	modification-dependent	 target	 gene	 expression,	 we	 used	 RNA	 interference	 to	 silence	
both	HATs	 in	 the	wild	 type	cell	 line	U-2932.	The	specific	depletion	of	CREBBP	or	EP300,	or	of	both	
HATs	combined,	reduced	H3K14,	K18	and	K27	acetylation	(Fig.	1C,	Fig.	S1C-F).	A	genomic	locus	that	is	
believed	 to	 be	 regulated	 by	 histone	 acetylation	 in	 B-cells,	 especially	 on	 residues	 modified	 by	
CREBBP/EP300,	 is	 the	 HLA	 locus.	 Chromatin	 immunoprecipitation	 using	 H3K18-acetyl-specific	 and	
H3K27-acetyl-specific	antibodies	followed	by	qPCR	confirmed	that	the	CREBBP/EP300-wild	type	cell	
line	U-2932	 indeed	exhibits	 strong	acetylation	of	K18	and	K27	at	 regulatory	elements	upstream	of	
the	HLA-DRA	transcription	start	site,	but	not	at	downstream	regions	of	the	gene	or	the	MyoD	control	
gene	(Fig.	1D).	The	loss	of	CREBBP	and	EP300	expression	significantly	reduced	HLA	transcript	levels,	
but	did	not	affect	an	irrelevant	control	gene	(Fig.	1E).	The	combined	results	indicate	that	the	CREBBP	
and	 EP300	 genomic	 loci	 are	 recurrently	mutated	 in	 both	 ABC-	 and	 GCB-DLBCL	 cell	 lines,	 and	 that	
their	gene	products	contribute	to	histone	H3	acetylation	and	promote	active	transcription	in	DLBCL	
cells	at	a	locus	known	to	be	specifically	regulated	by	this	epigenetic	mechanism.	
	
Genome	 editing	 of	 CREBBP	 mimicking	 a	 patient	 mutation	 reduces	 histone	 acetylation	 and	 HLA	
expression,	but	does	not	affect	in	vitro	growth	kinetics	
We	next	devised	a	strategy	that	allowed	us	to	mutate	one	allele	of	the	CREBBP	locus	in	the	wild	type	
U-2932	cell	 line	and	to	thereby	mimic	a	previously	 identified	patient	mutation,	at	position	A4171T,	
leading	to	a	premature	truncation	of	CREBBP	at	amino	acid	K1323X	and	the	loss	of	a	functional	HAT	
domain.	We	aimed	to	mutate	only	one	allele	because	most	patient	mutations	in	CREBBP	and	EP300	
are	mono-allelic.	 Genome	 editing	 was	 accomplished	 by	 CRISPR	 technology	 using	 guide	 RNAs	 that	
were	designed	 to	 promote	 the	 excision	of	 exon	23,	 one	of	 12	 exons	 encoding	 the	HAT	domain	of	
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CREBBP	(Fig.	S2A).	 In	 five	of	>100	examined	clones	the	excision	event	had	resulted	 in	a	frame	shift	
leading	 to	 a	 premature	 (mono-allelic)	 truncation	 of	 CREBBP.	 The	 resulting	 protein	 lacks	 the	 C-
terminus	and	more	than	half	of	the	HAT	domain	(Fig.	2A,	Fig.	S2B).	Whereas	control,	unedited	clones	
expressed	copious	amounts	of	full	 length	CREBBP,	the	mutant	clones	exhibited	a	clear	reduction	of	
full	 length	CREBBP	and	instead	featured	an	extra	band	representing	the	truncated	protein	(Fig.	2A).	
The	 expression	 of	 EP300	 was	 not	 affected	 by	 genomic	 editing	 of	 the	 CREBBP	 locus,	 with	 the	
exception	of	one	clone	(Fig.	2A).	As	expected,	H3	acetylation	was	reduced	 in	the	clones	expressing	
full	 length	 CREBBP	 from	 only	 one	 allele	 relative	 to	 the	 wild	 type	 clones	 (Fig.	 2A).	 Transcriptional	
profiling	 of	 five	 mutant	 and	 five	 wild	 type	 clones	 by	 RNA	 sequencing	 revealed	 over	 100	 strongly	
differentially	 regulated	 genes	 due	 to	 partial	 loss	 of	 CREBBP	 activity	 (Fig.	 2B,	 Dataset	 S1,	 GEO	
accession	 number	 GSE89879).	 The	 dominant	 biological	 process	 as	 determined	 by	 gene	 ontology	
analysis	was	“antigen	processing	and	presentation”,	as	numerous	MHCII	genes,	as	well	as	the	master	
regulator	of	MHCII	expression,	CIITA,	were	among	the	most	differentially	regulated	genes	(Fig.	2B).	
Loss	of	MHCII	expression	due	to	CREBBP	loss	was	confirmed	by	qRT-PCR	for	HLA-DRA	and	HLA-DRB1	
transcripts	(Fig.	2C),	confirming	the	results	obtained	by	siRNA-mediated	knock-down	of	CREBBP	and	
EP300.	 Other	 interesting	 CREBBP	 target	 genes	 (downregulated	 in	 mutant	 clones)	 include	 CREBBP	
itself	 and	 the	 surface	 receptors	CD19,	 CD74,	 S1PR1,	 IFNAR2	 and	CD52.	 Surprisingly,	 almost	 half	 of	
dysregulated	genes	were	up-regulated	in	the	mutant	clones	despite	the	fact	that	CREBBP	adds	active	
(rather	than	repressive)	histone	marks	(Fig.	2B,	Dataset	S1).	We	next	examined	the	growth	properties	
of	the	ten	clones	under	various	culture	conditions	in	vitro;	all	clones	grew	equally	fast	in	standard	cell	
culture	media,	 irrespective	of	 their	CREBBP	 status	 (Figure	 S2C,D),	 and	even	under	exposure	 to	 the	
histone	 deacetylase	 (HDAC)	 inhibitors	 PBA	 or	 VPA	 (Fig.	 S2E,F).	 Similarly,	 we	 could	 not	 detect	
differential	 susceptibility	 to	 HDAC	 inhibitors	 of	 our	CREBBP/EP300	 wild	 type	 and	mutant	 cell	 lines	
(Fig.	 S2G,H).	 The	 combined	 results	 indicate	 that	 HAT	 inactivation	 has	 profound	 effects	 on	 global	
histone	H3	acetylation	and	affects	the	expression	of	numerous	genes,	most	notably	MHCII	genes,	but	
does	not	confer	obvious	growth	advantages	in	in	vitro	culture	systems.	
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Monoallelic	 CREBBP	 inactivation	 promotes	 subcutaneous	 and	 orthotopic	 growth	 of	 xenografted	
DLBCL	cell	lines	in	immunocompromised	mice	
We	 next	 subcutaneously	 transplanted	 a	 subset	 of	 CREBBP-mutant	 and	 wild	 type	 clones	 onto	 the	
flanks	of	NSG	mice,	and	determined	the	tumor	growth	over	time	and	at	the	study	end	point.	CREBBP-
mutant	clones	grew	faster,	and	had	reached	a	larger	tumor	weight	and	volume	at	the	study	endpoint	
than	wild	type	clones	(Fig.	3A,	Fig.	S3A).	The	same	effect	was	observed	in	a	mouse	strain	expressing	
various	human	 cytokines	 that	have	been	knocked	 into	 the	 respective	murine	 loci	 (termed	MISTRG	
mice	due	to	knock-in	of	M-CSF,	IL-3,	Sirp1a,	thrombopoietin,	GM-CSF	in	the	Rag2-/-IL2Rg-/-	background	
(13))	(Fig.	3B,	Fig.	S3B).	We	next	assessed	whether	U2932	clones	would	engraft	in	lymphoid	organs	of	
mice	upon	intravenous	delivery;	in	NSG	mice	this	was	only	the	case	after	subcutaneous	passaging,	as	
had	 been	 described	 previously	 (14).	 Interestingly,	 subcutaneously	 passaged	 CREBBP+/-	 clones	
engrafted	more	readily	than	their	CREBBP+/+	counterparts	in	recipient	bones	(Fig.	S3C),	indicating	that	
CREBBP	loss	may	confer	a	growth	advantage	in	this	orthotopic	but	passage-dependent	model.	Most	
notably,	 however,	 we	 observed	 that	 both	CREBBP-wild	 type	 and	 –mutant	 clones	 engrafted	 in	 the	
bone	 marrow	 of	 MISTRG	 mice	 even	 without	 prior	 passaging	 (Fig.	 3C),	 with	 involvement	 of	 the	
kidneys	 and	ovaries	 observed	 in	 some,	 but	 not	 all	mice	 (Fig.	 S3D);	 involvement	 of	 other	 lymphoid	
organs	 such	 as	 the	 spleen	 was	 not	 observed	 with	 U2932	 cells.	 CREBBP+/-	 clones	 engrafted	 more	
readily	than	CREBBP+/+	clones	in	the	bone	marrow	of	MISTRG	mice	(Fig.	3C),	suggesting	that	the	loss	
of	CREBBP	confers	a	growth	advantage	in	this	novel	orthotopic	model.	Interestingly,	CREBBP–mutant	
clones	exhibited	 lower	HLA-DR	expression	even	after	extended	growth	 in	vivo	 (Fig.	3D).	hCD20	was	
stained	 for	 comparison,	 and	 did	 not	 differ	 among	 mutant	 and	 wild	 type	 clones	 (Fig.	 3D).	 The	
combined	 results	 suggest	 that	 CREBBP	 inactivation	 confers	 a	 growth	 advantage	 in	 vivo	 despite	
comparable	 in	 vitro	 growth	 rates,	 and	 introduce	 a	 novel	model	 of	DLBCL	 xenotransplantation	 that	
supports	orthotopic	growth	without	prior	conditioning	of	human	lymphoma	cells.	
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Germinal	center	B-cell	hyperproliferation	and	loss	of	MHCII	expression	upon	deletion	of	Crebbp		
We	 next	 sought	 to	 establish	 a	 mouse	 model	 that	 would	 allow	 the	 specific	 mono-	 and	 bi-allelic	
deletion	 of	 Crebbp	 and	 Ep300	 in	 the	 germinal	 center	 (GC)	 B-cell	 compartment.	 To	 this	 end,	 we	
crossed	mice	expressing	Cre	recombinase	under	the	activation-induced	cytidine	deaminase	promoter	
(AID-Cre)	with	mice	harboring	floxed	Crebbp	or	Ep300	alleles.	The	composite	strains	were	immunized	
intraperitoneally	with	sheep	red	blood	cells	(SRBCs)	to	induce	AID-Cre	activity	and	GC	formation.	The	
expected	excision	of	floxed	alleles	due	to	AID-Cre	activity	in	the	GC	compartment	was	verified	by	the	
parallel	 immunization	 of	AID-Cre	 x	 loxP-stop-loxP-RFP	 reporter	mice	 (Fig.	 S4A,B).	 Five	 consecutive	
rounds	 of	 SRBC	 immunization	 induced	 GC	 formation	 in	 the	 spleen	 and	 an	 increase	 in	
CD19+CD95+CD38low	GC	B-cells	(Fig.	4A,B).	Interestingly,	the	deletion	of	one	or	both	alleles	of	Crebbp	
led	 to	 hyperproliferation	 of	 the	 GC	 compartment	 relative	 to	Crebbp-proficient	 animals;	 this	 effect	
was	observed	for	all	GC	B-cells	(Fig.	4A,B),	irrespective	of	which	of	three	alternative	gating	strategies	
was	 used	 to	 identify	 them	 (Fig.	 S4C),	 as	 well	 as	 for	 centroblasts	 and	 centrocytes	 that	 were	
differentiated	based	on	their	CD86	and	CXCR4	expression	(Fig.	4B,	Fig.	S4C,D).	The	plasmablast	and	
plasmacyte	pools	increased	due	to	immunization	but	were	not	visibly	affected	by	loss	of	Crebbp	(Fig.	
S4E,F).	Strikingly,	quite	 the	opposite	effects	were	observed	upon	deletion	of	one	or	both	alleles	of	
Ep300:	Ep300-deficient	mice	 generated	 lower	 numbers	 of	GC	B-cells,	 centroblasts	 and	 centrocytes	
upon	immunization	(Fig.	4A,B,	Fig.	S4D).	To	obtain	additional	complementary	information	on	the	GC	
compartment	 of	 the	 same	 mice,	 we	 stained	 spleen	 sections	 cut	 at	 various	 depths	 for	 Ki67	 and	
quantified	GC	numbers	and	size;	this	approach	revealed	that	the	size	of	individual	GCs,	but	not	their	
multiplicity,	 accounts	 for	 the	 increase	 in	 GC	 B-cells	 in	 Crebbp-mutant	 mice,	 and	 the	 decrease	 in	
Ep300-mutant	mice	(Fig.	4C,	Fig.	S4G).		
GC	 B-cells	 lacking	 one	 or	 both	 alleles	 of	 either	 Ep300	 or	 Crebbp	 further	 exhibited	 reduced	MHCII	
expression	 relative	 to	 Crebbp/Ep300-proficient	 GC	 B-cells;	 this	 was	 true	 for	 all	 GC	 B-cells,	 and	
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especially	for	centroblasts	(Fig.	4D,E,	Fig.	S4H).	The	loss	of	Ep300	mirrored	the	effects	of	Crebbp	loss	
on	 MHCII	 expression	 (Fig.	 4D,E,	 Fig.	 S4H).	 Finally,	 to	 examine	 whether	 the	 loss	 of	 Crebbp	would	
promote	MYC-driven	 lymphomagenesis,	we	crossed	AID-Cre	 x	Crebbpfl/wt	mice	with	a	mouse	 strain	
that	expresses	MYC	under	the	control	of	the	immunoglobulin	heavy	chain	enhancer	(Emu-MYC)	(15).	
Interestingly,	the	loss	of	one	Crebbp	allele	was	sufficient	to	significantly	accelerate	the	formation	of	
MYC-driven	nodal	B-cell	 lymphomas	but	was	not	sufficient	 to	 induce	 lymphomas	 in	 the	absence	of	
this	 second	 hit	 (Fig.	 4F);	 furthermore,	 we	 found	 that	 upon	 intravenous	 transplantation	 of	 equal	
numbers	 of	 tumor	 cells	 from	 Crebbp-proficient	 or	 -deficient	 lymphoma-bearing	 donors,	 the	 latter	
cells	engrafted	more	readily	in	the	lymph	nodes	and	spleens	of	wild	type	recipient	mice,	and	retained	
their	low	MHCII	expression	relative	to	Crebbp-proficient	cells	(Fig.	4G,	Fig.	S4I).	We	conclude	from	the	
combined	results	that	HATs	control	MHCII	expression	in	both	human	and	murine	B-cells	and	that	the	
loss	of	Crebbp,	but	not	of	Ep300,	additionally	contributes	to	the	immunization-induced	expansion	of	
the	GC	compartment;	both	phenomena	appear	to	predispose	to	malignant	transformation.						
	
The	loss	of	MHCII	expression,	or	CD4+	T-cell	depletion,	promotes	MYC-driven	lymphomagenesis	
To	 address	 whether	 the	 loss	 of	 MHCII	 expression	 that	 results	 from	 HAT	 inactivation	 promotes	
lymphomagenesis,	 we	 crossed	 mice	 lacking	 MHCII	 with	 Emu-MYC	mice.	 MHCII-/-	 mice	 developed	
MYC-driven	tumors	earlier	than	their	MHCII+/+	littermates;	however,	the	fraction	of	mice	that	did	not	
develop	 lymphomas	 at	 all	 in	 the	 time	 frame	 of	 observation	 (80	 days)	was	 comparable	 in	 the	 two	
groups	 (Fig.	 5A).	MHCII-/-	mice	 lack	MHCII-restricted	 CD4+	 T-cells	 in	 all	 lymphoid	 tissues	 (Fig.	 S5A),	
which	 might	 explain	 their	 enhanced	 predisposition	 to	 MYC-driven	 lymphomagenesis.	 To	 dissect	
whether	the	loss	of	MHCII	affects	lymphomagenesis	in	immunocompetent	mice	with	normal	CD4+	T-
cell	 frequencies,	 we	 transplanted	 100.000	MHCII-/-	 or	MHCII+/+	MYC-expressing	 tumor	 cells	 pooled	
from	 the	 axillary	 and	 inguinal	 lymph	 nodes	 of	 two	 donors	 per	 genotype	 into	 wild	 type	 C57BL6	
recipients	and	 recorded	 the	 tumor	 incidence.	Whereas	only	2	out	of	16	 recipients	of	MHCII+/+	 cells	
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developed	 lymphomas	with	 this	 low	dose	of	cells,	10	of	17	recipients	of	MHCII-/-	 cells	did	 (Fig.	5B).	
The	 differential	 engraftment	 of	 MHCII-proficient	 and	 –deficient	 cells	 was	 reflected	 in	 on	 average	
significantly	higher	spleen	and	lymph	node	weights	of	recipients	of	MHCII-/-	cells,	and	more	efficient	
engraftment	of	tumor	cells	in	bone	marrow	(Fig	5C).	Finally,	to	confirm	that	MHCII-restricted	T-cells	
indeed	 control	 lymphomagenesis	 in	 the	 serial	 transplantation	 model,	 we	 depleted	 CD4+	 T-cells	
starting	at	either	one	day	before	injection	of	a	saturating	dose	of	1	Mio	tumor	cells,	or	once	palpable	
tumors	 had	 formed	 in	 the	 inguinal	 and	 axillary	 lymph	 nodes	 on	 day	 11	 post	 transplantation.	 The	
depletion	 of	 CD4+	 T-cells	 was	 efficient	 in	 all	 examined	 organs	 (Fig.	 S5B)	 and	 strongly	 enhanced	
lymphoma	 cell	 engraftment	 and	 growth	 in	 lymph	nodes,	 spleen	 and	bone	marrow,	 especially	 if	 T-
cells	were	depleted	from	the	start	of	the	experiment	(Fig.	5D).		The	combined	results	are	consistent	
with	 the	 notion	 that	 the	 loss	 of	MHCII	 expression	 confers	 a	 tumor	 cell	 survival	 benefit,	 especially	
during	 lymphoma	 initiation,	 indicating	 that	 immune	 surveillance	 driven	 by	 CD4+	 T-cells	 limits	
lymphomagenesis	in	immunocompetent	animals.	
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Discussion	
In	this	study,	we	have	combined	targeted	re-sequencing	of	the	genes	encoding	the	HATs	CREBBP	and	
EP300	 with	 experimental	 approaches	 using	 cell	 cultures	 and	 mouse	 models	 to	 shed	 light	 on	 the	
potential	 tumor	 suppressive	 activity	 of	 HATs	 in	 DLBCL.	 As	 expected	 from	 previous	 studies	 using	
patient	cohorts	 (2,	8,	10),	our	panel	of	11	DLBCL	cell	 lines	confirmed	that	 inactivating	mutations	 in	
CREBBP	and	EP300	are	common,	mono-allelic	and	mutually	exclusive	and	typically	compromise	the	
enzymatic	activity	of	both	enzymes,	 leading	 to	strongly	 reduced	 levels	of	histone	H3	acetylation	of	
the	 lysine	 residues	 K14,	 K18	 and	 K27.	 The	 siRNA-mediated	 knockdown	 of	 CREBBP,	 alone	 and	
especially	 in	 combination	 with	 EP300,	 strongly	 reduced	 global	 H3	 acetylation	 at	 the	 same	 three	
residues,	but	did	not	affect	the	acetylation	of	non-histone	proteins.		
To	model	HAT	function	in	DLBCL	cell	 lines	in	a	manner	that	would	recapitulate	the	dosage	effect	of	
mono-allelic	mutational	CREBBP	 inactivation	 and	 a	 possible	 dominant	 negative	 effect	 of	 truncated	
protein	 resulting	 from	 the	 introduction	of	premature	 stop	 codons,	we	 introduced	a	 typical	patient	
mutation	 mono-allelically	 into	 a	 CREBBP/EP300-wild	 type	 cell	 line.	 The	 expression	 of	 truncated	
CREBBP	 resulted	 in	 reduced	 global	 H3K18	 acetylation	 and	 large	 changes	 in	 gene	 expression.	 The	
dominant	 category	of	dysregulated	genes	 contained	 the	 various	alleles	of	MHCII	 genes	 involved	 in	
antigen	presentation,	as	well	as	their	master	regulator,	the	transcription	factor	CIITA,	which	could	be	
confirmed	 not	 only	 by	 targeted	 qRT-PCR	 in	 the	 human	 DLBCL	 cell	 line	 clones,	 but	 also	 in	murine	
germinal	 center	 (GC)	 B-cells	 upon	 Cre-mediated	 excision	 of	 Crebbp	 or	 Ep300.	 The	 dependence	 of	
MHCII	expression	on	active	histone	marks	added	by	HATs	thus	appears	to	be	a	universal	feature	of	
murine	 and	 human	 B-cells,	 which	 could	 further	 be	 confirmed	 experimentally	 by	 chromatin	
immunoprecipitation	 of	 the	 HLA-DRA	 locus	 with	 acetyl-H3-specific	 antibodies.	 The	 transcriptional	
signature	we	identified	here	to	be	linked	to	CREBBP-mediated	histone	modification	is	consistent	with	
previous	 reports	 showing	 that	 CREBBP	 regulates	 super-enhancer	 networks	 with	 central	 roles	 in	
GC/post-GC	cell	fate	decisions,	including	genes	involved	in	signal	transduction	by	the	B-cell	receptor	
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and	 CD40	 receptor,	 transcriptional	 control	 of	 GC	 and	 plasma	 cell	 development,	 and	 antigen	
presentation	(11,	12).	
The	reduced	expression	of	MHCII	is	an	obvious,	but	not	the	only	consequence	of	HAT	inactivation	in	
CREBBP-mutant	DLBCL	cell	 lines.	Mutant	clones	grow	faster	when	subcutaneously	transplanted	into	
NSG	mice	and	CREBBP-mutant	 tumors	are	 larger	and	heavier	at	 the	study	endpoint	 than	wild	 type	
tumors.	 The	 same	was	 true	 in	 Rag2-/-γc-/-	mice	 that	 express	 several	 human	 cytokines,	 allowing	 for	
efficient	engraftment	of	various	human	 immune	cell	compartments	 (13).	The	differential	growth	 in	
both	xenograft	models	is	unlikely	to	be	due	to	immune	evasion	caused	by	MHCII	downregulation,	a	
mechanism	 that	 has	 been	 proposed	 to	 explain	 the	 lack	 of	 T-cell	 activation	 and	 proliferation	 in	
CREBBP-mutant	 FL	 (16).	 In	 FL,	CREBBP	mutations	 are	 known	 to	 occur	within	 the	 earliest	 inferable	
progenitor,	 result	 in	 decreased	 MHCII	 expression	 on	 tumor	 B-cells,	 and	 correlate	 with	 decreased	
frequencies	of	tumor-infiltrating	CD4+	helper	T-cells	 (16).	As	anti-tumor	 immunity	driven	by	CD4+	T-
cells	can	be	ruled	out	in	the	two	immunocompromised	xenograft	models	used	here,	CREEBP-mutant	
tumors	 must	 benefit	 from	 additional	 cell-intrinsic	 growth	 advantages	 conferred	 by	 loss	 of	 HAT	
activity	in	this	setting.	The	same	was	observed	in	genetically	manipulated	mice,	where	the	loss	of	one	
or	both	alleles	of	Crebbp	led	to	hyperproliferation	of	the	GC	B-cell	compartment	upon	immunization.	
The	 dysregulated	 expansion	 of	 the	 GC	 compartment	 likely	 provides	 a	 setting	 in	 which	 additional	
mutations	can	accumulate	and	early	clonal	lesions	can	arise,	especially	given	the	genomic	instability	
that	 is	 an	 inherent	 feature	 of	 GC	 B-cells;	 indeed,	 Crebbp	 loss	 accelerated	 MYC-driven	
lymphomagenesis	 in	 both	 spontaneous	 and	 serial	 transplantation	 models.	 We	 hypothesize	 that	
CREBBP	 mutations	 confer	 two	 distinct	 benefits	 during	 DLBCL	 pathogenesis,	 one	 promoting	
unrestricted	growth	during	 the	GC	reaction,	and	the	other	promoting	 immune	evasion.	Our	 results	
showing	 enhanced	 engraftment	 of	 MHCII-negative,	 MYC-expressing	 lymphoma	 cells	 into	
immunocompetent	 mice	 provide	 experimental	 evidence	 for	 the	 concept	 that	 the	 loss	 of	 MHCII	
expression	indeed	promotes	immune	evasion	in	this	setting.	This	result	was	phenocopied	by	CD4+	T-
cell	 depletion,	 indicating	 that	MHCII-restricted	 T-cells	 control	 early	 events	 of	 lymphomagenesis	 in	
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immunocompetent	 hosts,	 either	 through	 direct	 cytotoxic	 effects	 on	 tumor	 B-cells	 or	 by	 creating	 a	
cytokine	milieu	that	 is	not	conducive	to	tumor	initiation	and/or	progression.	 Interestingly,	only	one	
of	the	two	biological	functions	of	CREBBP	appears	to	be	shared	by	EP300.	Ep300	 inactivation	in	the	
mouse	GC	compartment	downregulates	MHCII	expression	to	an	extent	that	is	comparable	to	Crebbp	
inactivation;	in	contrast,	the	hyperproliferation	of	the	GC	compartment	upon	immunization	was	not	
seen	in	Ep300	mutant	mice,	which	rather	exhibited	a	contraction	of	their	GC	B-cells.	Thus,	EP300	and	
CREBBP	 have	 both	 shared	 and	 distinct	 activities,	 which	 in	 turn	 is	 reflected	 by	 the	 much	 more	
common	mutational	inactivation	of	CREBBP	than	of	EP300	in	DLBCL	patients	(2,	8,	10).		
In	addition	to	their	role	as	bona	fide	tumor	suppressors	in	DLBCL	and	mechanistic	contribution	to	the	
control	 of	 the	GC	 reaction	 and	 antigen	presentation,	wild	 type	HAT	 activity	 also	 confers	 clear	 and	
previously	 unknown	 benefits	 in	 terms	 of	 patient	 survival	 (17).	 Furthermore,	 HAT	 mutational	
inactivation	likely	predicts	treatment	responses	to	novel	targeted	therapies	with	epigenetically	acting	
drugs,	 such	 as	 the	 HDAC3	 inhibitors	 (11,	 18).	 In	 summary,	 our	 results	 provide	 evidence	 for	 two	
complementary	tumor	suppressive	mechanisms	in	GC	B-cells	that	depend	on	HAT	enzymes,	of	which	
one	controls	proliferation	in	a	cell-autonomous	manner,	and	the	other	sensitizes	malignant	B-cells	to	
CD4+	T-cell-mediated	tumor	control.					
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Materials	and	Methods	
DLBCL	 cell	 lines	 and	 targeted	 re-sequencing	 of	 CREBBP	 and	 EP300.	 The	 panel	 of	 DLBCL	 cell	 lines	
used	here	included	five	of	GCB	DLBCL	subtype	(SU-DHL-4,	SU-DHL-6,	SU-DHL-10,	SU-DHL-16,	and	RC-
K8)	and	six	of	ABC	DLBCL	subtype	(U-2932,	OCI-Ly3,	OCI-Ly10,	SU-DHL2,	SU-DHL5,	and	RIVA).	Culture	
conditions,	 transfections,	 CRISPR	 manipulations,	 RNA	 sequencing,	 ChIP-PCR	 and	 Western	 blotting	
techniques	are	all	described	in	the	supplemental	methods.		
	
Animal	 experimentation.	 The	 mouse	 strains	 B6.Cg-Crebbptm1Jvd/J,	 B6.129P2-Ep300tm2Pkb/J,	 B6.Cg-
Tg(IghMyc)22Bri/J	and	B6;129P2-Aicdtm1CreMnz/J		were	obtained	from	the	Jackson	Laboratories.	MHCII-
/-,	 NOD/SCID/IL2Rγ-/-	 (NSG)	 and	 M-CSFh;IL-3/GM-CSFh;hSIRPAtg;TPOh;Rag2-;γc-	 (MISTRG)(13)	 mice	
were	obtained	 from	a	 local	 repository.	Ep300fl/fl	 and	Crebbpfl/fl	mice	were	crossed	 to	AIDcre	animals	
and	 MYC-transgenic	 mice	 were	 crossed	 with	 MHCII-/-	 mice	 and	 AIDcre	 x	 Crebbpfl/fl	 mice	 to	 obtain	
composite	 strains.	6-8	week	old	mice	were	 immunized	3-6	 times	every	 second	week	with	200µl	of	
10%	sheep	red	blood	cells	(Innovative	Research,	Michigan,	USA)	and	sacrificed	10	days	after	the	last	
immunization.	 All	 flow	 cytometry	 procedures	 are	 described	 in	 the	 supplemental	 methods.	 For	
xenotransplantation	studies,	CREBBP+/-	and	CREBBP+/+	U2932	clones	(10x106	cells	in	150µl	PBS)	were	
injected	subcutaneously	into	both	flanks	of	6-8	week	old	NSG	or	MISTRG	mice,	or	intravenously	into	
MISTRG	mice	in	the	orthotopic	model.	Once	palpable	tumors	had	formed	in	the	subcutaneous	model	
(~40	mm3),	 the	 volume	of	 the	 tumors	was	measured	 by	 calipers	 and	 calculated	 using	 the	 formula	
(a2xb)/2,	where	a	is	the	shorter	and	b	the	longer	tumor	dimension.	For	serial	transplantation	studies,	
100.000	to	1	Mio	tumor	cells	pooled	from	the	axillary	and	inguinal	lymph	nodes,	or	from	spleens	of	
mice	were	 cryopreserved	 in	 FCS	 +	 10%	DMSO,	 and	were	 subsequently	 injected	 intravenously	 in	 a	
volume	of	100	µl.	All	animal	studies	were	reviewed	and	approved	by	the	Zürich	Cantonal	Veterinary	
Office	(licenses	227/2015,	235/2015).		
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Figure	legends	
Fig.	1.	The	mutational	inactivation	or	deletion	of	CREBBP	and	EP300	affects	histone	H3	acetylation	
and	 HLA	 expression	 in	 DLBCL	 cell	 lines.	 (A)	 Targeted	 re-sequencing	 of	 CREBBP	 and	 EP300	 (all	 31	
exons)	 in	 the	panel	of	11	 indicated	DLBCL	cell	 lines.	Chromosomal	deletions	and	translocations	are	
listed	 as	 reported	 in	 the	 literature.	 (B)	Protein	 lysates	 from	 the	 DLBCL	 cell	 lines	 shown	 in	 A	were	
subjected	 to	 immunoblot	analysis	using	antibodies	specific	 for	CREBBP,	EP300,	α-tubulin,	H3K14ac,	
H3K18ac,	H3K27ac,	and	total	H3.	Blots	shown	are	representative	of	 two	 independent	experiments.	
Color	code	in	A	and	B:	blue,	wild	type;	black,	mutant	CREBBP;	red:	mutant	EP300.	Asterisks	indicate	
truncated	CREBBP	protein.	 (C)	U-2932	 cells	were	 treated	with	 control	 siRNA	or	 siRNAs	 specific	 for	
CREBBP,	EP300,	or	both	 (pool);	protein	 lysates	were	harvested	after	72h	and	96h	and	subjected	to	
immunoblot	 analysis	 using	 the	 indicated	 antibodies.	 A	 representative	 experiment	 is	 shown	 along	
with	 the	 densitometric	 quantification	 of	 four	 independent	 experiments.	 (D)	 Profile	 of	 histone	
acetylation	at	 the	HLA-DRA	 locus.	ChIP	of	U-2932	cells	was	performed	with	H3K18ac,	H3K27ac	and	
control	IgG	antibody	and	was	followed	by	PCRs	of	the	8	regions	indicated	on	the	X-axis.		(E)	Relative	
expression	of	HLA-DRA	and	HLA-DRB1	and	of	WEE1	as	control,	normalized	to	RPLP32,	as	assessed	by	
qRT-PCR	of	U-2932	 cells	 treated	with	 siRNAs	 for	 48h	 as	 described	 in	 C.	Data	 in	 C	 and	 E	 represent	
means	+	SD	of	4	biological	replicates.	*p<0.05;	**p<0.01;	***p<0.001;	****p<0.0001.			
	
Fig.	2.	Genome	editing	of	CREBBP	in	U-2932	cells	reduces	HLA	expression.	(A)	Protein	lysates	from	
four	 CREBBP+/+	 and	 five	 CREBBP+/-	 clones	were	 subjected	 to	 immunoblot	 analysis	 with	 antibodies	
specific	for	CREBBP,	EP300,	α-tubulin,	and	H3K18ac.	(B)	Transcriptional	profiling	of	five	CREBBP+/+	and	
five	CREBBP+/-	 clones	was	performed	by	 RNA	 sequencing.	 The	 top	 100	most	 strongly	 differentially	
regulated	genes	(log2	ratio	≥	0.4	and	≤	-0.4)	are	displayed	in	a	heat	map.	Genes	of	the	HLA	family,	as	
well	 as	 CREBBP	 and	 CIITA	 are	 annotated.	 (C)	 Relative	 expression	 of	 HLA-DRA	 and	 HLA-DRB1	
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compared	 to	RPLP0	as	 assessed	by	qRT-PCR	of	 the	 clones	 shown	 in	B,	 plus	 several	 additional	wild	
type	clones.	**p<0.01.	
	
Fig.	 3.	Growth	of	 xenografted	U-2932	CREBBP+/+	 and	CREBBP+/-	 clones	 in	NSG	 and	MISTRG	mice.	
(A,B)		Ten	million	cells	of	two	CREBBP+/+	and	two	CREBBP+/-	clones	were	subcutaneously	transplanted	
onto	the	flanks	of	NSG	(A)	or	MISTRG	(B)	mice.	Tumor	volumes	were	measured	with	calipers	every	
other	 day	 from	 day	 10	 until	 day	 29	 post	 transplantation	 and	 at	 the	 study	 end	 point.	 The	 tumor	
weight	was	determined	at	the	study	endpoint.	Each	symbol	represents	one	tumor.	Results	from	two	
pooled	experiments	are	shown	for	each	mouse	strain.	(C,D)	Ten	million	cells	of	three	CREBBP+/+	and	
three	CREBBP+/-	 clones	were	 intravenously	 transplanted	 into	MISTRG	mice;	mice	were	 sacrificed	at	
four	weeks	post	transplantation	and	assessed	with	respect	to	their	human	tumor	burden	in	the	bone	
marrow	 (C),	 as	well	 as	 the	expression	of	hCD20	and	HLA-DR	on	bone-marrow-infiltrating	 tumor	B-
cells	 (D).	 Pooled	 data	 from	 two	 studies	 are	 shown	 in	 C,	 and	 data	 from	 one	 of	 the	 two	 studies	 is	
shown	in	D.	p-values	were	calculated	using	the	Mann-Whitney	test.	*p<0.05;	**p<0.01;	***p<0.001.			
	
Fig.	 4.	Deletion	 of	 Crebbp	 within	 the	 GC	 compartment	 promotes	 GC	 expansion,	 reduces	 MHCII	
expression	 and	 accelerates	 MYC-driven	 lymphomagenesis.	 (A,B)	 Littermates	 with	 either	 no	 (wt),	
one	(fl/wt)	or	two	(fl/fl)	floxed	alleles	of	Crebbp	or	Ep300,	which	additionally	express	Cre	under	the	
control	 of	 the	AID	 promoter,	were	 immunized	 4	 times	 at	 biweekly	 intervals	with	 sheep	 red	 blood	
cells	and	sacrificed	10	days	after	the	last	injection.	Representative	flow	cytometry	plots	of	splenic	GC	
B-cells	 are	 shown	 in	 A,	 and	 the	 frequencies	 of	 CD95+CD38low	 GC	 B-cells,	 as	 well	 as	 of	 Cxcr4+	
centroblasts	 (CB)	are	 shown	 in	%	of	all	CD19+	 live	cells	 in	B.	Non-immunized	mice	are	 included	 for	
comparison.	Pooled	data	from	three	to	five	independent	cohorts	are	shown.	(C)	The	GC	number	and	
GC	area	per	spleen	area	(arbitrary	units)	of	the	mice	shown	in	B,	as	quantified	based	on	Ki67	staining	
of	 three	 spleen	 sections	 per	 mouse.	 	 (D,E)	Median	 fluorescence	 intensity	 (MFI)	 of	 MHCII	 surface	
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expression	on	GC	B-cells	and	centroblasts	of	the	mice	shown	in	B	and	C;	representative	histograms	
are	shown	in	D.	(F)	Mice	of	the	three	indicated	genotypes	were	immunized	at	regular	14	day	intervals	
and	monitored	for	clinical	symptoms	and	enlarged	lymph	nodes	indicating	lymphoma	development.	
Moribund	mice	were	sacrificed	and	their	survival	time	since	the	first	 immunization	was	plotted.	(G)	
Four	and	three	wild	type	C57BL/6	mice	were	i.v.	injected	with	0.5	Mio	Crebbpfl/wt	or	Crebbpwt/wt	MYC-
expressing	 lymphoma	cells,	 respectively,	 that	were	harvested	 from	the	pooled	 inguinal	and	axillary	
lymph	 nodes	 of	 lymphoma-bearing	 donors.	Mice	were	 assessed	with	 respect	 to	 their	 lymph	 node	
weights	(inguinal	and	axillary	LNs	are	plotted	separately	for	each	recipient	and	share	the	same	color	
code)	and	lymph	node	B-cell	MHCII	expression	at	the	study	endpoint	(28	days	post	transplantation),	
relative	 to	 two	 non-transplanted	 controls.	 p-values	were	 calculated	 using	 the	Mann-Whitney	 test.	
*p<0.05;	**p<0.01;	***p<0.001;	****p<0.0001.			
	
Fig.	5.	Tumor	cell-intrinsic	MHCII	loss	and	CD4+	T-cell	depletion	both	confer	enhanced	susceptibility	
to	MYC-driven	lymphomagenesis.	(A)	Mice	of	the	indicated	genotypes	were	immunized	at	regular	14	
day	 intervals	with	 sheep	 red	 blood	 cells	 and	monitored	 for	 clinical	 symptoms	 and	 enlarged	 lymph	
nodes	 indicating	 lymphoma	 development.	 Moribund	 mice	 were	 sacrificed	 and	 their	 survival	 time	
since	the	first	 immunization	was	plotted.	(B,C)	16	and	17	wild	type	C57BL/6	mice	were	 i.v.	 injected	
with	0.1	Mio	MHCII+/+	or	MHCII-/-	MYC-expressing	lymphoma	cells,	respectively,	that	were	harvested	
from	 the	 pooled	 inguinal	 and	 axillary	 LNs	 of	 lymphoma-bearing	 donors.	Mice	were	 assessed	with	
respect	to	lymphoma	incidence	(B)	and	spleen	and	LN	weights	(one	data	point	per	mouse,	the	mean	
of	 the	 four	 inguinal	and	axillary	 LNs	 is	 shown)	and	B-cell	 frequencies	 in	bone	marrow	at	 the	 study	
endpoint	 (C,	 28	 days	 post	 transplantation),	 relative	 to	 two	non-transplanted	 controls.	 Pooled	 data	
from	two	studies	are	shown	in	B	and	C,	except	for	the	BM	data	which	were	from	one	study	only.		(D)	
18,	17	and	7	wild	type	C57BL/6	mice	were	 i.v.	 injected	with	1	Mio	splenic	MHCII+/+	MYC-expressing	
lymphoma	cells,	 respectively,	 and	assessed	with	 respect	 to	 spleen	and	 LN	weights	 (one	data	point	
per	 mouse,	 the	 mean	 of	 two	 inguinal	 and	 axillary	 LNs	 is	 shown)	 and	 B-cell	 frequencies	 in	 bone	
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marrow	 at	 the	 study	 endpoint	 (28	 days	 post	 transplantation),	 relative	 to	 five	 non-transplanted	
controls.	 Mice	 were	 additionally	 treated	 weekly	 with	 CD4-specific	 or	 isotype	 control	 antibody,	
starting	either	at	one	day	before	 transplantation,	or	once	palpable	 tumors	had	 formed	 (at	11	days	
p.t.).	 Pooled	 data	 from	 two	 studies	 are	 shown	 in	 D.	 p-values	 were	 calculated	 using	 the	 Mann-
Whitney	test.	*p<0.05;	**p<0.01;	***p<0.001.			
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Supporting	Information	
SI	figure	legends		
	
Fig.	 S1.	 The	histone	acetyl-transferases	CREBBP	and	EP300	 regulate	H3K14,	but	not	H3K9	or	p53	
acetylation.	(A,B)	Protein	lysates	of	the	indicated	11	DLBCL	cell	lines	were	subjected	to	immunoblot	
analysis	 using	 antibodies	 for	 TFIIH,	 total	 p53,	 ac-p53,	 H3K9ac,	 and	 α-tubulin.	 Blots	 shown	 are	
representative	of	 two	 independent	experiments.	 (C)	U-2932	cells	were	electroporated	with	control	
siRNA	or	siRNAs	specific	for	CREBBP,	EP300,	or	both	(pool);	protein	lysates	were	harvested	48h	post	
transfection	 and	 used	 for	 immunoblot	 analysis	with	 antibodies	 specific	 for	 CREBBP,	 EP300,	 and	α-
tubulin.	 (D)	Densitometric	 quantification	of	 the	 knock	down	efficiency	of	 CREBBP	and	EP300	of	 all	
four	experiments	shown	in	Figure	1C	and	E,	as	shown	representatively	for	one	experiment	in	C.	Note	
that	there	 is	compensatory	CREBBP	expression	due	to	EP300	depletion,	but	not	vice	versa.	 (E,F)	U-
2932	 cells	 were	 treated	 with	 control	 siRNA	 or	 siRNAs	 specific	 for	 CREBBP,	 EP300,	 or	 both	 (pool);	
protein	 lysates	were	 harvested	 after	 72h	 and	 96h	 and	 subjected	 to	 immunoblot	 analysis	 using	 an	
antibody	for	H3K14ac.	A	representative	experiment	of	two	is	shown	in	E,	along	with	its	densitometric	
quantification	 in	 F.	 p-values	 were	 calculated	 using	 the	 Mann-Whitney	 test.	 *p<0.05;	 **p<0.01;	
***p<0.001.		
	
Fig.	S2.	CRISPR-mediated	genome	editing	of	CREBBP.	(A)	Schematic	of	the	strategy	used	for	excising	
exon	23	of	CREBBP	with	CRISPR/Cas9	technology.	(B)	PCR	confirmation	of	the	deletion.	(C,D)	Viability	
assessment	 of	 CREBBP	 wild	 type	 and	mutant	 clones.	 Five	 wild	 type	 and	 five	 mutant	 clones	 were	
seeded	at	a	density	of	0.3x106/ml.	Cell	number/ml	is	shown	in	C;	the	viability	as	assessed	by	Cell	Titer	
Blue	assay	 is	shown	in	D.	(E-H)	To	assess	the	sensitivity	to	HDAC	inhibitors,	CRISPR	clones	(E,F)	and	
DLBCL	 cell	 lines	 (G,H)	 were	 seeded	 at	 a	 density	 of	 0.4x106/ml	 and	 treated	 with	 either	 sodium	 4-
phenylbutuyrate	 (PBA)	 or	 valproic	 acid	 sodium	 salt	 (VPA)	 (Sigma	 Aldrich)	 at	 the	 indicated	 final	
concentrations;	viability	was	assessed	by	Cell	Titer	Blue	assay.	Data	in	E-H	are	represented	as	means	
of	2	independent	experiments.	
	
Fig.	S3.	Growth	of	xenografted	U-2932	CREBBP+/+	and	CREBBP+/-	 clones	 in	NSG	and	MISTRG	mice.	
(A,B)		Ten	million	cells	of	two	CREBBP+/+	and	two	CREBBP+/-	clones	were	subcutaneously	transplanted	
onto	the	flanks	of	NSG	(A)	or	MISTRG	(B)	mice.	Tumor	volumes	were	measured	with	calipers	every	
other	day	 from	day	10	until	day	29	post	 transplantation	 for	each	mouse.	Each	 line	 represents	one	
mouse.	 Results	 from	 two	 pooled	 experiments	 are	 shown	 for	 each	 mouse	 strain.	 (C)	 Six	 million	
subcutaneously	passaged	cells	of	two	CREBBP+/+	and	two	CREBBP+/-	U2932	clones	were	intravenously	
transplanted	 into	NSG	mice;	mice	were	 sacrificed	at	 four	weeks	post	 transplantation	and	assessed	
with	respect	to	their	human	tumor	burden	in	the	bone	marrow.	(D)	Representative	images	of	H&E-
stained	 sections	 of	 a	 tumor-bearing	 kidney	 and	 a	 healthy	 kidney	 (both	 from	 MISTRG	 mice)	 are	
shown.	Scale	bar	is	1000	µm.		
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Fig.	 S4.	Germinal	 center	 B-cell	 hyperproliferation	 and	 loss	 of	MHCII	 expression	 upon	deletion	 of	
Crebbp.	(A,B)	AIDcre/wt	and	AIDcre/wt	RFPfl/wt	mice	were	immunized	once	intraperitoneally	with	200µl	of	
10%	sheep	red	blood	cells	and	sacrificed	10	days	afterwards.	The	percentage	of	germinal	center	B-
cells	 of	 CD19+	 live	 cells	 were	 assessed	 by	 flow	 cytometry.	 Germinal	 center	 B-cells	 were	 gated	 as	
singlets/live/CD19+/CD95+CD38low.	 RFP+	 GC	 B	 cells	 were	 gated	 as	 singlets/live/CD19+/	
CD95+CD38low/RFP+.	Representative	 FACS	plots	 are	 shown	 in	A;	 the	quantification	of	RFP+	 germinal	
center	 B-cells	 after	 immunization	 is	 shown	 for	 two	 independent	 experiments	 in	 B.	 Each	 symbol	
represents	 one	 mouse.	 Horizontal	 lines	 indicate	 means.	 Statistical	 analysis	 was	 done	 by	 Mann-
Whitney	test.	(C)	Gating	strategy	for	germinal	center	(GC)	B	cells,	centroblasts	(CB),	and	centrocytes	
(CC).	GC	B	cells	can	be	gated	using	three	different	strategies:	1-	singlets/live/CD19+/CD95+CD38low,	2-	
singlets/live/CD19+B220+/CD95+PNAhigh,	 and	 3-	 singlets/live/CD19+/B220+PNAhigh.	 Centroblasts	 are	
Cxcr4hiCD86low;	 centrocytes	 are	 Cxcr4lowCD86low.	 (D)	 Littermates	with	 either	 no	 (wt),	 one	 (fl/wt)	 or	
two	(fl/fl)	floxed	alleles	of	Crebbp	or	Ep300,	which	additionally	express	Cre	under	the	control	of	the	
AID	 promoter,	 were	 immunized	 4	 times	 at	 biweekly	 intervals	 with	 sheep	 red	 blood	 cells	 and	
sacrificed	 10	 days	 after	 the	 last	 injection.	 Non-immunized	 mice	 are	 shown	 as	 controls.	 The	
quantification	of	centrocytes	(CC)	in	%	of	live	CD19+	cells	 is	shown	for	the	animals	included	in	main	
Figure	4B.	 (E)	Gating	strategy	for	plasmablasts	 (PB)	and	plasma	cells	 (PC).	Plasmablasts	and	plasma	
cells	were	gated	as	singlets/live/CD3-/CD138+B220+	and	singlets/live/CD3-/CD138+B220-,	respectively.	
(F)	Quantification	of	the	percentages	of	plasmablasts	and	plasma	cells,	of	the	mice	shown	in	E	and	in	
Figure	 4B.	 (G)	 Representative	 image	 of	 a	 Ki67-stained	 spleen.	 Arrows	 indicate	 germinal	 centers.	
Spleens	were	formalin-fixed	and	embedded	in	paraffin,	and	three	sections	per	spleen	approximately	
100	 µm	 apart	 were	 stained	 with	 a	 Ki67-specific	 antibody.	 Images	 were	 acquired	 on	 a	 Leica	
microscope.	(H)	Median	fluorescence	intensity	(MFI)	of	MHCII	expression	of	the	centrocytes	shown	in	
D.	 In	 D,F	 and	H,	 each	 symbol	 represents	 one	mouse.	Pooled	 data	 from	 three	 to	 five	 independent	
cohorts	 are	 shown.	 	 (I)	 Four	 and	 three	 wild	 type	 C57BL/6	 mice	 were	 i.v.	 injected	 with	 0.5	 Mio	
Crebbpfl/wt	or	Crebbpwt/wt	MYC-expressing	lymphoma	cells,	respectively,	that	were	harvested	from	the	
pooled	 inguinal	 and	 axillary	 lymph	 nodes	 of	 lymphoma-bearing	 donors.	 Mice	 were	 assessed	 with	
respect	 to	 their	 spleen	weights	and	splenic	B-cell	MHCII	expression	at	 the	study	endpoint	 (28	days	
post	transplantation),	relative	to	two	non-transplanted	controls.	p-values	were	calculated	using	the	
Mann-Whitney	test.	*p<0.05;	**p<0.01;	***p<0.001.				
	
Fig.	 S5.	 Tumor	 cell-intrinsic	 MHCII	 loss	 and	 CD4+	 T-cell	 depletion	 both	 confer	 enhanced	
susceptibility	to	MYC-driven	lymphomagenesis.	(A)	Mice	of	the	indicated	genotypes	were	assessed	
with	respect	to	their	CD4+	T-cell	compartment	in	the	blood.	(B)	18,	17	and	7	wild	type	C57BL/6	mice	
were	 i.v.	 injected	 with	 1	 Mio	 splenic	 MHCII+/+	 MYC-expressing	 lymphoma	 cells,	 respectively,	 and	
additionally	treated	weekly	with	CD4-specific	or	isotype	control	antibody,	starting	either	at	one	day	
before	transplantation,	or	once	palpable	tumors	had	formed	(at	11	days	p.t.).	Graphs	show	the	CD4+	
T-cell	depletion	efficiency	in	the	spleen,	lymph	nodes	(LN)	and	bone	marrow	(BM);	pooled	data	from	
two	studies	are	shown.	p-values	were	calculated	using	the	Mann-Whitney	test.	*p<0.05;	**p<0.01;	
***p<0.001.			
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Dataset	S1.	List	of	100	top	significantly	differentially	expressed	genes	between	CREBBP+/+	and	
CREBBP+/-	clones	as	identified	by	RNA-sequencing.	The	cut-off	for	the	log2	ratio	was	specified	as	≥	0.4	
and	≤	-0.4.	 	
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Supplemental	materials	and	methods	
DLBCL	cell	culture,	transfection	and	cell	viability	assays	
Cell	lines	were	maintained	at	37°C,	5%	CO2	in	a	humidified	atmosphere	in	IMDM	(RIVA,	OCI-Ly3,	OCI-
Ly10)	 or	 RPMI	 (SU-DHL2	 and	 SU-DHL5)	 supplemented	with	 10%	 or	 20%	 (SU-DHL-4,	 SU-DHL-6,	 SU-
DHL-10,	 SU-DHL-16,	RC-K8,	U-2932)	heat-inactivated	FBS	and	antibiotics.	 For	 the	purpose	of	 siRNA	
treatment,	0.5x106	DLBCL	cells	were	nucleoporated	using	the	Amaxa	Nucleofector	II	device	such	that	
the	final	concentration	of	siRNA	was	100µM.	The	following	siRNAs	were	purchased	from	Qiagen:	Hs	
EP300	7	FlexiTube	siRNA	Cat	no:	SI02626267,	Hs	CREBBP8	FlexiTube	siRNA	Cat	no:	SI02633099	and	
Control	AllStars	Negative	Control	siRNA	Cat	no:	SI03650318.	Cells	were	harvested	48h,	72h,	or	96h	
post	transfection	for	protein	or	RNA	extraction.	For	viability	assays,	cells	were	seeded	at	a	density	of	
0.3x106/ml.	 50μl	 of	 cell	 suspension	 were	 transferred	 into	 96-well	 plates	 containing	 50μl	 fresh	
medium	in	triplicates.	20μl	of	CellTiter-Blue	reagent	(Promega)	was	added	and	plates	were	incubated	
for	4h	at	37°C,	5%	CO2	in	a	humidified	atmosphere.	Viability	was	subsequently	assessed	by	measuring	
fluorescence	at	560Ex/590Em	using	a	SpectraMax	M5	microplate	reader.	
	
CRISPR/Cas9	manipulation	of	U-2932	cells	
The	 PX458	 plasmid	 used	was	 obtained	 from	 Addgene	 (#48138:	 pSpCas9(BB)-2A-GFP).	 Guide	 RNAs	
were	designed	using	the	Zheng	Lab	online	tool	(http://crispr.mit.edu/)	and	cloned	into	PX458.	Guide	
RNA	efficiency	was	 tested	by	calcium	phosphate	 transfection	of	HEK	293T	cells	and	 the	best	gRNA	
combination	was	chosen.	gRNA	1	fwd:	CAC	CGT	GCA	CTT	ACC	CTC	ATG	AC;	rev:	AAA	CGT	CAT	GAG	
GGT	AAG	AAT	GCA	C;	gRNA	2	fwd:	CAC	CGC	AGC	ATT	CAG	ATA	GTT	TGT,	rev:	AAA	CAC	AAA	CTA	TCT	
GAA	 TGC	 TGC	 0.5x106	 U-2932	 cells	 were	 nucleoporated	 with	 3μg	 of	 the	 plasmid	 containing	 the	
desired	 gRNAs	 using	 the	 Amaxa	 Nucleofector	 II	 device,	 and	 48h	 post	 transfection	 the	 cells	 were	
single	 cell	 sorted	 for	 GFP	 expression	 into	 pre-conditioned	 medium.	 Single	 cell	 cultures	 were	
subsequently	 screened	 by	 gDNA	 isolation	 (adapted	 from	 the	 KAPA	 Mouse	 Genotyping	 Kit,	 KAPA	
Biosystems),	and	PCR	based	verification	of	the	deletion	(fwd:	TCA	GGG	TGA	GTT	GTT	TCC	CC,	rev:	TTA	
GAG	AGT	GCT	GGC	CAA	CA).	
	
RNA	sequencing	and	data	analysis	
RNA	from	DLBCL	cell	 lines	as	well	as	CRISPR/Cas9	edited	U-2932	was	 isolated	using	the	NucleoSpin	
RNA	 kit	 (Macherey-Nagel).	 RNA	 quality	 was	 assessed	 by	 Bioanalyzer	 2100	 followed	 by	 library	
preparation	 using	 the	 TruSeq	 RNA	 Sample	 Prep	 Kit	 v4	 (Illumina).	 Sequencing	 was	 subsequently	
performed	on	the	Illumina	HiSeq	2500	instrument.	RNA-seq	reads	were	quality-checked	with	fastqc,	
which	 computes	 various	 quality	 metrics	 for	 the	 raw	 reads.	 RNA-seq	 reads	 were	 mapped	 to	 the	
GRCh38	reference	human	genome	using	STAR	and	reads	were	counted	according	 to	Ensembl	gene	
annotation	 using	 the	 featureCounts	 function	 in	 the	 Rsubread	 Bioconductor	 package.	 Statistical	
analysis	of	differential	expression	was	conducted	with	the	DESeq2	package.	
	
Quantitative	RT-PCR	
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RNA	was	 extracted	 using	 the	 Nucleospin	 RNA	 kit.	 1μg	 of	 total	 RNA	was	 reverse	 transcribed	 using	
SuperScriptIII	 reverse	transcriptase	 (Invitrogen).	For	qRT-PCR,	Lightcycler	480	Cyber	Green	Master	 I	
(Roche)	was	used	followed	by	analysis	on	a	Lightcycler	480	 instrument.	Samples	were	measured	 in	
duplicates.	 For	 all	 primer	 pairs,	 the	 efficiency	 was	 calculated	 by	 performing	 dilution	 series	
experiments.	 Target	 mRNA	 abundance	 was	 subsequently	 calculated	 relative	 to	 human	 RPLP0	 or	
RPLP32.	The	 following	primers	were	used:	RPLP0,	 fwd:	CCA	GCT	CTG	GAG	AAA	CTG	CTG,	 rev:	CAG	
CAG	CTG	GCA	CCT	TAT	TGG;	RPLP32,	fwd:	GAA	GTT	CCT	GGT	CCA	CAA	CG,	rev:	5'-	GCG	ATC	TCG	GCA	
CAG	TAA	G;	CREBBP,	fwd:	GTC	CAG	TTG	CCA	CAA	GCA	C,	rev:	CAT	TCG	GGA	AGG	AGA	AAT	GG;	EP300,	
fwd:	GCC	AAG	TAC	TTC	AGC	TAC	CCA	GT,	rev:	GGC	ATC	AGT	GCC	TGT	CGT	AG;	HLA-DRA,	fwd:	GCA	
CTG	GGA	GTT	TGA	TGC	TC,	rev:	AGG	GCA	CAC	ACC	ACG	TTC;	HLA-DRB1,	fwd:	ACT	ACG	GGG	TTG	TGG	
AGA	GC,	rev:	GAG	CAG	ACC	AGG	AGG	TTG	TG;	WEE1,	fwd:	ATT	GGC	GGG	CTC	TGT	TGA	T,	rev:	GCC	
CAC	GCA	GAG	AAA	TAT	CG.	
	
Western	blotting		
Protein	extracts	were	made	in	RIPA	buffer	(50mM	Tris-HCl,	pH	8.0,	150mM	sodium	chloride,	1%	NP-
40,	0.5%	sodium	deoxycholate,	0.1%	SDS)	 supplemented	with	2mM	sodium	orthovanadate,	15mM	
sodium	pyrophosphate,	10mM	sodium	fluoride	and	1X	complete	protease	inhibitor	cocktail	(Roche).	
Protein	extracts	for	CREBBP/EP300	were	prepared	in	MNase	buffer	1	(0.3M	sucrose,	15mM	Tris	pH	
7.5,	 60mM	KCl,	 15mM	NaCl,	 5mM	MgCl2,	 0.1mM	 EGTA,	 05mM	DTT,	 0.5%	NP-40,	 and	 1%	 Sodium	
deoxycholate)	+	MNase	buffer	2	(0.3M	sucrose,	85mM	Tris	pH	7.5,	3mM	MgCl2,	2mM	CaCl2,	and	10U	
S7	MNase,	Roche).	The	reaction	was	stopped	by	addition	of	EDTA	with	a	final	concentration	of	5mM.	
Protein	 concentrations	 were	 determined	 using	 BCA	 assay	 (Pierce)	 or	 Bradford	 assay	 (Bio-Rad)	 for	
MNase-isolated	proteins,	and	equal	amounts	were	separated	by	SDS/PAGE	(4–20%	Mini-PROTEAN®	
TGX™	 Precast	 Protein	 Gels,	 BIO-RAD)	 followed	 by	 transfer	 onto	 nitrocellulose	 membranes.	
Membranes	were	probed	with	antibodies	against	α-tubulin	(DM1A,	Sigma	Aldrich),	p300	(N-15,	Santa	
Cruz	 Biotechnology),	 CBP	 (A-22,	 Santa	 Cruz	 Biotechnology),	 TFIIH	 p89	 (s-19,	 Santa	 Cruz	
Biotechnology),	 and	 p53	 antibody	 (9282),	 Acetyl-p53	 (Lys382),	 CBP	 (D6C5),	 Histone	H3	 XP	 (D1H2),	
Acetyl-Histone	 H3	 Lys9	 (C5B11),	 Acetyl-Histone	 H3	 Lys27	 XP	 (D5E4),	 Acetyl-Histone	 H3	 Lys18	
(D8Z5H),	and	Acetyl-Histone	H3	Lys14	(D4B9)	(all	from	Cell	Signaling).	
	
Flow	cytometric	analysis		
Cells	 isolated	from	mouse	spleens,	 lymph	nodes,	blood	or	bone	marrow	were	treated	with	ACK	red	
blood	cell	lysis	buffer	pH	7.2-7.4	(150mM	NH4Cl,	10mM	KHCO3,	0.1mM	Na2EDTA)	and	passed	through	
a	 40µM	cell	 strainer	 to	produce	 single-cell	 suspensions.	 Cells	were	 subsequently	 stained	using	 the	
following	fluorescent-labeled	anti-mouse	antibodies:	PE-Cy7	conjugated	anti-CD95/FAS	(Jo2,	Becton	
Dickinson),	PerCP-Cy5.5	conjugated	anti-CD86	(GL-1,	Biolegend),	Pacific	Blue™	conjugated	anti-I-A/I-E	
(M5/114.15.2,	Biolegend),	Purified	Rat	Anti-Mouse	CD16/CD32	(93,	Biolegend),	Brilliant	Violet™	650	
anti-CD45	 (30-F11,	 Biolegend),	 Brilliant	 Violet™	 605	 anti-CD4	 (RM4-5,	 Biolegend),	 PE-Cy7	 anti-TCR-
beta	chain	(H57-597,	Biolegend),	APC	anti-CD8a	(53-6.7,	Biolegend),	FITC	anti-CD19	(1D3,	Biolegend),	
Alexa	 Fluor®	 700	 anti-I-A/I-E	 (M5/114.15.2,	 Biolegend),	 FITC	 anti-CD4	 (RM4-5,	 Biolegend),	 Pacific	
Blue™	anti-CD8a	 (53-6.7,	 Biolegend),	 PE	 anti-CD45	 (30-F11,	 Biolegend),	 Fluorescein	 labeled	Peanut	
Agglutinin	 (PNA,	 VectorLaboratories),	 and	 Fixable	 Viability	 Dye	 eFluor®	 780,	 APC	 conjugated	 anti-
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CD19	 (eBio1D3),	 FITC	 conjugated	 anti-CD38	 (90),	 PE	 conjugated	 anti-CXCR4	 (2B11),	 eFluor®	 450	
conjugated	 anti-CD45R/B220	 (RA3-6B2),	 PE-Cy7	 conjugated	 CD23	 (B3B4),	 FITC	 conjugated	 anti-
CD21/CD35	 (eBio4E3),	 and	 PE	 conjugated	 anti-CD3e	 (145-2C11)	 all	 from	 ebio/Affymetrix.	 The	
following	fluorescent-labeled	anti-human	antibodies	were	used:	APC	anti-CD45	(2D1),	FITC	anti-CD19	
(HIB19),	Pacific	Blue™	anti-CD20	(HI47),	PE	anti-HLA-DR	(LN3),	and	Hu	FCR	binding	inhibitor	purified	
all	from	ebio/Affymetrix.	Data	were	acquired	on	CyAn	ADP	(Beckman	Coulter)	or	LSR	FORTESSA	(BD)	
flow	cytometers	and	analyzed	with	the	FlowJo	software	package	(TreeStar).		
	
Treatment	of	mice	with	antibodies	
Anti-mouse	CD4	(BE0119,	Clone:	YTS)	and	rat	IgG2b	isotype	control	(BE0090,	Clone:	LTF-2)	antibodies	
were	purchased	from	BioXCell.	Mice	were	administered	a	500µg	dose	one	day	before	i.v.	injection	of	
tumor	cells,	then	once	per	week	with	a	250µg	until	end	of	the	study	(28	days),	or	starting	only	once	
palpable	tumors	had	formed.	
	
Ki67	staining	of	germinal	centers	
CONFIRM	 anti-Ki-67	 (30-9)	 Rabbit	 Monoclonal	 Primary	 Antibody	 (Roche)	 was	 used	 for	 staining	 of	
proliferating	cells	within	germinal	centers	on	formalin-fixed	paraffin-embedded	spleen	sections	using	
a	 Ventana	 automated	 slide	 stainer.	 This	 was	 provided	 as	 a	 service	 by	 the	 Laboratory	 for	 Animal	
Model	 Pathology	 (LAMP)	 of	 the	 Institut	 für	 Veterinärpathologie	 of	 the	 University	 of	 Zürich.	 Three	
sections	approximately	100	µm	apart	were	assessed	per	mouse	spleen.	The	images	were	acquired	on	
a	Leica	microscope	and	Image	J	was	used	for	area	assessment.	Germinal	centers	were	 identified	as	
Ki67-positive	areas	within	blue	areas.	Background	staining,	mostly	on	the	peripheries	of	 the	spleen	
sections	was	not	included.		
	
ChIP-PCR	
ChIP	was	performed	as	previously	described	(19).	100	x106	cells	were	 fixed	with	1%	formaldehyde,	
lysed,	and	sonicated	(Branson	Sonicator;	Branson),	resulting	in	sheared	chromatin	of	an	average	size	
of	200	bp.	2	μg	of	antibodies	H3K27ac	(ab4729,	Abcam),	and	H3K18ac	(ab1191,	Abcam),	or	control	
rabbit	 IgG	 (sc-2027,	 Santa	 Cruz	 Biotechnology)	 were	 added	 to	 25	 µg	 of	 precleared	 sample	 and	
immunoprecipitated	 overnight	 at	 4	 °C.	 The	 complexes	 were	 purified	 using	 protein	 A	 beads	
(Invitrogen)	 followed	 by	 elution	 from	 the	 beads	 and	 decrosslinking.	 DNA	 was	 purified	 using	 PCR	
purification	 columns	 (Macherey	 Nagel)	 and	 quantified	 by	 quantitative	 PCR.	 The	 following	 primers	
were	used	for	qPCR:	GAPDH,	fwd:	AGA	AGG	CTG	GGG	CTC	ATT	TG,	rev:	AGG	GGC	CAT	CCA	CAG	TCT	
TC;	MyoD,	 fwd:	CCT	CTT	TCG	GTC	CCT	CTT	TC,	 rev:	 TTCCAAACCTCTCCAACACC;	XL4,	 fwd:	CAG	AGA	
AAG	GGA	ACT	GAA	AGT	CAT	TT,	rev:	TTA	TGA	CAC	TGT	TTA	GTC	CTA	GAA	CAC	TGA;	-600bp,	fwd:	ATG	
AGA	TAC	AAT	GCC	AGC	CAT	CC,	rev:	ACA	GTT	GGA	GAG	TTT	GCG	TAA	GG;	-300bp,	fwd:	TGT	CCC	TTA	
CGC	AAA	CTC	TCC,	rev:	ACA	CAA	GAT	ACT	CCG	TTC	ATT	GG;	WXY,	fwd:	GAT	CTC	TTG	TGT	CCT	GGA	
CCC	TTT	GCA	AGA	ACC	CT,	rev:	CCC	AAT	TAC	TCT	TTG	GCC	AAT	CAG	AAA	AAT	ATT	TTG;	+1500bp,	fwd:	
CTC	CGT	CTC	AAA	CAA	CCA	AAC	C,	rev:	ACC	AAC	ACC	AAG	GGA	ATA	ATG	AAC;	+3500bp,	fwd:	TTC	CGC	
AAG	TTC	CAC	TAT	CTC	C,	rev:	CGA	GTT	TCA	CAC	AAG	CAT	CAT	AGG.	
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Statistics	All	 statistical	 analyses	 were	 performed	 using	 Graph	 Pad	 Prism	 software.	 Graphs	 represent	means	plus	SD	of	at	 least	two	independent	experiments	and	statistical	analysis	was	performed	using	two-tailed	student’s	t-test	for	RT-PCR	data,	and	using	two-tailed	Mann-Whitney	test	for	in	
vivo	studies.	Cox	regression	analysis	and	the	log-rank	test	were	performed	on	patient	cohorts	to	determine	survival	probability	in	multivariate	and	univariate	analyses,	respectively.		
	
Data	availability		The	 RNA-sequencing	 dataset	 is	 publicly	 available	 on	 the	 GEO	 Accession	 viewer	 with	 the	accession	number	GSE89879.		(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89879).		
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Fig.	S1.	
	 	
36	
	
	
Fig.	S2.	
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Fig.	S3.	
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Fig.	S4.	
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Fig.	S5.	
